ACAD
Closed
Acadia Pharmaceuticals Inc
21.36
-0.21 (-0.97%)
Last Update: 01 Jul 2025 23:02:00
Yesterday: 21.57
Day's Range: 21.16 - 22.1
Send
sign up or login to leave a comment!
When Written:
18.82
ACADIA Pharmaceuticals Inc is a biopharmaceutical company headquartered in San Diego, California. The company is focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders.
ACADIA's lead product, Nuplazid (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company is also developing other potential treatments for CNS disorders such as dementia-related psychosis, schizophrenia, and major depressive disorder.
ACADIA was founded in 1993 and went public in 2004. The company has partnerships with major pharmaceutical companies such as Allergan and Biogen, and has a global presence with operations in the United States, Europe, and Asia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
ACADIA's lead product, Nuplazid (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company is also developing other potential treatments for CNS disorders such as dementia-related psychosis, schizophrenia, and major depressive disorder.
ACADIA was founded in 1993 and went public in 2004. The company has partnerships with major pharmaceutical companies such as Allergan and Biogen, and has a global presence with operations in the United States, Europe, and Asia.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!